CAT
Caterpillar Inc.
CAT has a slight edge over PXS overall, supported by stronger valuation and stronger fundamentals.
PXS
Pyxis Tankers Inc.
PXS offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
PXS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
PXS's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT has the edge over PXS in the historical PE scenario, which offers more potential upside but is not a forecast.
PXS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 1.6x | $1.32 | -77% |
| Fair | 2.4x | $1.92 | -66% |
| Forward | 3.7x | $5.65 | — |
| Current | 7x | $5.65 | — |
| Expensive | 18x | $14.30 | +153% |
Historical ranges are pointers, not guarantees.
PXS's PE is in its expensive range at 7.0x. If earnings grow as analysts expect, today's price would be 3.7x next year's earnings.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
PXS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for PXS, with profitability improving.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT has the stronger earnings trend. Trailing diluted EPS is up 31% for CAT versus PXS down 70%.
PXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.52 | +88% |
| Q3 2024 | $2.76 | +18% |
| Q2 2024 | $2.73 | +7.1% |
| Q1 2024 | $2.54 | -6.3% |
| Q4 2023 | $3.57 | +237% |
| Q3 2023 | $2.34 | +$2.37 |
| Q2 2023 | $2.55 | +$3.42 |
| Q1 2023 | $2.71 | +$4.11 |
| Q4 2022 | $1.06 | +$2.40 |
PXS's earnings per share have fallen from their peak: $0.81 over the past year, against $3.57 in late 2023.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT has the edge over PXS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT's operating margin was 20% last quarter, up 3.1 points from the same quarter a year ago.
PXS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $12.1M | +33% |
| Q1 2026 | $10M | +3.9% |
| Q4 2025 | $10.5M | -12% |
| Q3 2025 | $9.7M | -30% |
| Q2 2025 | $9.2M | -34% |
| Q1 2025 | $9.6M | -19% |
| Q4 2024 | $12M | -9.2% |
| Q3 2024 | $13.8M | +24% |
PXS's revenue is recovering but still below its 2022 peak: $12M last quarter, up 33% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 36% | +46 points |
| Q1 2026 | 34% | +17 points |
| Q4 2025 | 29% | +19 points |
| Q3 2025 | 22% | -12 points |
| Q2 2025 | -9.5% | -54 points |
| Q1 2025 | 16% | -22 points |
| Q4 2024 | 11% | -35 points |
| Q3 2024 | 34% | -2.5 points |
PXS has the edge over CAT on profitability, with a higher operating margin.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT generated $11.3B in free cash flow over the past year, up 26% from the year before.
PXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $5.8M | +88% |
| Q1 2026 | $3.4M | -17% |
| Q4 2025 | $2.3M | -62% |
| Q3 2025 | $3.3M | +78% |
| Q2 2025 | $3.1M | +$17.6M |
| Q1 2025 | $4.1M | +$23.9M |
| Q4 2024 | $6.1M | +$7.3M |
| Q3 2024 | $1.9M | +$23.4M |
PXS has the edge over CAT on cash flow, with more consistent year-over-year improvement.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over PXS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
PXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -98.3K shares |
| 1 year | -1.7% | -172K shares |
| 3 years | -19% | -2.4M shares |
| 5 years | +40% | +2.9M shares |
| Available history | +94% | +5M shares |
PXS has 10M diluted shares, down 1.7% from a year ago, with $867,216 in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $74,849 |
| Q1 2026 | $586,000 |
| Q4 2025 | $204,363 |
| Q3 2025 | $2,004 |
| Q2 2025 | $10,417 |
| Q1 2025 | $270,000 |
| Q4 2024 | $1.8M |
| Q3 2024 | $436,000 |
PXS spent $867,216 buying back its own shares over the past year, down 66% from the year before.
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has the edge over PXS on leverage, with a lower net debt burden relative to earnings.
PXS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.1x | Healthy |
| Q1 2026 | 3.4x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 3.7x | Elevated |
| Q2 2025 | 3.4x | Elevated |
| Q1 2025 | 2.6x | Moderate |
| Q4 2024 | 2.5x | Moderate |
| Q3 2024 | 1.3x | Healthy |
PXS's net debt is about 1.1 years of its operating earnings (EBITDA), down from 3.4 years a year ago.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
PXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.9 | Neutral |
| Stochastic | 40.3 | Neutral |
PXS's weekly RSI is 49 (neutral) and its Stochastic is 40 (neutral).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
PXS PE vs Industrials Sector
| Metric | PXS | Sector median | Relative |
|---|---|---|---|
| PE | 7x | 24x | 71% below |
| PE % | 72 | 58 | 14 pts above |
PXS has the edge over CAT on valuation relative to its sector.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
PXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.91 | 18% below |
| 20 week MA | $5.93 | 4.7% below |
| 50 week MA | $4.68 | 21% above |
| 100 week MA | $3.89 | 45% above |
| 200 week MA | $4.20 | 35% above |
PXS has the edge over CAT on trend strength, trading above more of its moving averages.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has finished every year since 2020 higher, and it's up 3.8% so far in 2026.
PXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.48 | $3.25 | -27% |
| 2021 | $3.25 | $2.15 | -34% |
| 2022 | $2.15 | $5.20 | +142% |
| 2023 | $5.20 | $4.17 | -20% |
| 2024 | $4.17 | $3.67 | -12% |
| 2025 | $3.67 | $2.95 | -20% |
| 2026 YTD | $2.95 | $5.65 | +92% |
PXS has the edge over CAT on returns for 2026, with the stronger performance.